Sera Prognostics Q2 net loss widens to $11.5M; cash runway extended to 2026

SERA PROGNOSTICS, INC.

2022-Q2 EPS reported -$0.77 revenue$116,000

Revenue of $78K, up from $20K in Q2 2021, but operating expenses rose to $11.8M from $7.4M.
Net loss of $11.5M ($0.29/share) vs $6.3M a year ago; cash & securities at $121M as of June 30.
PreTRM test now collects blood at 18-20 weeks; sensitivity ~90%, NPV 99% for preterm risk.
Company streamlined operations to fund operations into 2026 without additional financing.
Contracted several new self-insured employer plans for PreTRM testing as an advanced pregnancy benefit.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.